EP3355892A4 - Verfahren zur behandlung von muskeldystrophie - Google Patents

Verfahren zur behandlung von muskeldystrophie Download PDF

Info

Publication number
EP3355892A4
EP3355892A4 EP16852633.3A EP16852633A EP3355892A4 EP 3355892 A4 EP3355892 A4 EP 3355892A4 EP 16852633 A EP16852633 A EP 16852633A EP 3355892 A4 EP3355892 A4 EP 3355892A4
Authority
EP
European Patent Office
Prior art keywords
methods
treating muscle
muscle dystrophy
dystrophy
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16852633.3A
Other languages
English (en)
French (fr)
Other versions
EP3355892A1 (de
Inventor
Edward M. KAYE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
Original Assignee
Sarepta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sarepta Therapeutics Inc filed Critical Sarepta Therapeutics Inc
Priority to EP19207672.7A priority Critical patent/EP3653216A1/de
Publication of EP3355892A1 publication Critical patent/EP3355892A1/de
Publication of EP3355892A4 publication Critical patent/EP3355892A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
EP16852633.3A 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie Withdrawn EP3355892A4 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP19207672.7A EP3653216A1 (de) 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562235477P 2015-09-30 2015-09-30
US201662278866P 2016-01-14 2016-01-14
US201662293235P 2016-02-09 2016-02-09
US201662299952P 2016-02-25 2016-02-25
PCT/US2016/054534 WO2017059131A1 (en) 2015-09-30 2016-09-29 Methods for treating muscular dystrophy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP19207672.7A Division EP3653216A1 (de) 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie

Publications (2)

Publication Number Publication Date
EP3355892A1 EP3355892A1 (de) 2018-08-08
EP3355892A4 true EP3355892A4 (de) 2019-05-22

Family

ID=58424307

Family Applications (2)

Application Number Title Priority Date Filing Date
EP16852633.3A Withdrawn EP3355892A4 (de) 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie
EP19207672.7A Withdrawn EP3653216A1 (de) 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19207672.7A Withdrawn EP3653216A1 (de) 2015-09-30 2016-09-29 Verfahren zur behandlung von muskeldystrophie

Country Status (9)

Country Link
US (2) US20190054113A1 (de)
EP (2) EP3355892A4 (de)
JP (1) JP2018529715A (de)
CN (1) CN108738310A (de)
BR (1) BR112018006445A2 (de)
EA (1) EA201890811A1 (de)
HK (1) HK1258823A1 (de)
IL (1) IL258211A (de)
WO (1) WO2017059131A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2933332A1 (de) 2004-06-28 2015-10-21 The University Of Western Australia Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon
TR201816523T4 (tr) 2009-11-12 2018-11-21 Univ Western Australia Patolojilerin tedavisine yönelik antisens moleküller ve yöntemler.
TWI541024B (zh) 2010-09-01 2016-07-11 日本新藥股份有限公司 反義核酸
CN110218727A (zh) 2013-03-14 2019-09-10 萨勒普塔医疗公司 用于治疗肌营养不良的外显子跳跃组合物
US20140329762A1 (en) 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
US11083737B1 (en) * 2016-05-27 2021-08-10 Ptc Therapeutics, Inc. Methods of administering deflazacort therapy
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CN112399849A (zh) * 2018-06-26 2021-02-23 日本新药株式会社 含有反义寡核苷酸的组合物及其在迪谢内肌营养不良症的治疗中的用途
US20220152086A1 (en) * 2019-03-28 2022-05-19 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy with casimersen
AU2020368539A1 (en) 2019-10-16 2022-04-28 Massachusetts Institute Of Technology Engineered muscle targeting compositions
CN116507338A (zh) * 2020-09-21 2023-07-28 雷沃根生物医药有限公司 NF-κB介导的疾病的治疗
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
AR128918A1 (es) * 2022-03-30 2024-06-26 Biomarin Pharm Inc Oligonucleótidos que omiten el exón 51 de distrofina y sus aplicaciones

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH445129A (fr) 1964-04-29 1967-10-15 Nestle Sa Procédé pour la préparation de composés d'inclusion à poids moléculaire élevé
US3459731A (en) 1966-12-16 1969-08-05 Corn Products Co Cyclodextrin polyethers and their production
US3426011A (en) 1967-02-13 1969-02-04 Corn Products Co Cyclodextrins with anionic properties
US3453257A (en) 1967-02-13 1969-07-01 Corn Products Co Cyclodextrin with cationic properties
US3453259A (en) 1967-03-22 1969-07-01 Corn Products Co Cyclodextrin polyol ethers and their oxidation products
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1986005519A1 (en) 1985-03-15 1986-09-25 James Summerton Polynucleotide assay reagent and method
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
EP0786522A2 (de) 1992-07-17 1997-07-30 Ribozyme Pharmaceuticals, Inc. Enzymatische RNA-Moleküle zur Behandlung von stenotischen Zuständen
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5753613A (en) 1994-09-30 1998-05-19 Inex Pharmaceuticals Corporation Compositions for the introduction of polyanionic materials into cells
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
WO1999042091A2 (en) 1998-02-19 1999-08-26 Massachusetts Institute Of Technology Use of polycations as endosomolytic agents
WO2001047496A1 (en) 1999-12-29 2001-07-05 Mixson A James Histidine copolymer and methods for using same
US7070807B2 (en) 1999-12-29 2006-07-04 Mixson A James Branched histidine copolymers and methods for using same
PL2735568T3 (pl) 2006-05-10 2018-02-28 Sarepta Therapeutics, Inc. Analogi oligonukleotydowe mające kationowe połączenia pomiędzy podjednostkami
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
BR122020021379B1 (pt) * 2008-10-24 2021-05-11 Sarepta Therapeutics, Inc. oligômero morfolino fosforodiamidato, composição que compreende o mesmo e uso do dito oligômero para tratar distrofia muscular
KR20200133284A (ko) 2010-05-28 2020-11-26 사렙타 쎄러퓨틱스, 인코퍼레이티드 변형된 서브유니트간 결합 및/또는 말단 그룹을 갖는 올리고뉴클레오타이드 유사체
US20140329762A1 (en) * 2013-03-15 2014-11-06 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
MX388221B (es) * 2013-04-20 2025-03-19 Res Institute At Nationwide Children´S Hospital ADMINISTRACIÓN DE VIRUS ADENO-ASOCIADO RECOMBINANTE DE CONSTRUCCIONES DE POLINUCLÉOTIDOS U7snRNA DIRIGIDA AL EXÓN 2.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "Sarepta Therapeutics Reports Long-Term Outcomes through 168 Weeks from Phase IIb Study of Eteplirsen en in Duchenne Muscular Dystrophy", 12 January 2015 (2015-01-12), XP055580695, Retrieved from the Internet <URL:http://investorrelations.sarepta.com/static-files/be998766-867b-4104-8531-35f5b6046496> [retrieved on 20190412] *
JERRY R. MENDELL ET AL: "Eteplirsen for the treatment of Duchenne muscular dystrophy", ANNALS OF NEUROLOGY, vol. 74, no. 5, 10 September 2013 (2013-09-10), pages 637 - 647, XP055135317, ISSN: 0364-5134, DOI: 10.1002/ana.23982 *
See also references of WO2017059131A1 *

Also Published As

Publication number Publication date
US20210008095A1 (en) 2021-01-14
WO2017059131A1 (en) 2017-04-06
EP3355892A1 (de) 2018-08-08
JP2018529715A (ja) 2018-10-11
US20190054113A1 (en) 2019-02-21
CN108738310A (zh) 2018-11-02
IL258211A (en) 2018-05-31
EA201890811A1 (ru) 2018-09-28
EP3653216A1 (de) 2020-05-20
HK1258823A1 (zh) 2019-11-22
BR112018006445A2 (pt) 2018-12-11

Similar Documents

Publication Publication Date Title
EP3355892A4 (de) Verfahren zur behandlung von muskeldystrophie
EP3500289A4 (de) Verfahren zur behandlung von tracheobronchomalazie
EP3288382A4 (de) Verfahren zur behandlung von krebs
EP3331550A4 (de) Verfahren zur behandlung von myeloproliferativen erkrankungen
EP3426250A4 (de) Behandlungsverfahren
HUE052106T2 (hu) Eljárás rák kezelésére
EP3601536A4 (de) Behandlungsverfahren
EP3341392A4 (de) Zusammensetzungen und verfahren zur schmerzbehandlung
EP3374502A4 (de) Verfahren zur behandlung von hornhautdystrophien
EP3389657A4 (de) Verfahren zur behandlung von hyperalgesie
EP3341080A4 (de) Verfahren zur behandlung von krebs
HUE050124T2 (hu) Eljárás biopolimerek dezacetilezésére
EP3389634A4 (de) Verfahren zur behandlung von krebs
EP2968273A4 (de) Verfahren zur behandlung von muskeldystrophien
PT3265087T (pt) Método de tratamento com tradipitant
EP3442946A4 (de) Verfahren zur behandlung von krebs
PL3393468T3 (pl) Metody leczenia niedoboru odporności
EP3375108A4 (de) Selektives wlan
EP3375440A4 (de) Verfahren zur behandlung von mukositis
EP3389652A4 (de) Verfahren zur behandlung von krebs
EP3325006A4 (de) Verfahren zur behandlung von cd166-exprimierendem krebs
EP2971146A4 (de) Verfahren zur behandlung von bauchspeicheldrüsenkrebs
IL257764B (en) Methods for treatment of diseases
IL259178A (en) Methods for treating muscular dystrophy
EP3684342A4 (de) Behandlungsverfahren

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20180430

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20190425

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/573 20060101ALI20190417BHEP

Ipc: A61K 31/7088 20060101ALI20190417BHEP

Ipc: A61K 31/7125 20060101AFI20190417BHEP

Ipc: A61P 21/06 20060101ALI20190417BHEP

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1258823

Country of ref document: HK

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191126

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1258823

Country of ref document: HK